Global DPP-IV Inhibitors Markets 2016-2024 by Drugs (Sitagliptin, Vildagliptin, Saxagliptin & Others) & Segments (Sitagliptin, Saxagliptin, Linagliptin & Alogliptin)

DUBLIN, Oct. 17, 2018 /PRNewswire/ --

The "DPP-IV Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million.

The Global market is analyzed by the following Drugs:

• Sitagliptin
• Vildagliptin
• Saxagliptin
• Others

The US market is further analysed in terms of sales by the following drug Segments:

• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin

The report profiles 14 companies including many key and niche players such as:

• AstraZeneca Plc. (UK)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly and Company (USA)
• Merck & Co, Inc. (USA)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Novartis AG (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
  

Key Topics Covered:

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW
Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
Management of T2DM with DPP-4 Combination Therapy
FDA Approves Merck's First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy

3. THE DIABETES EPIDEMIC
Key Diabetes Statistics
Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market

4. AN OVERVIEW OF DRUG CLASSES IN ANTI-DIABETIC DRUGS CATEGORY
DPP-4 Inhibitors - Complementing Existing Approaches
Rationale for Use of DPP-4 Inhibitors
Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
DPP-IV Inhibitors Vis--vis SGLT2 Inhibitors
DPP-4 Inhibitors versus GLP-1 Receptor Agonists
Distinction between GLP-1 Receptor Agonists and DPP-4 Inhibitors
DPP-4 Inhibitors versus Sulfonylureas

5. A REVIEW OF SELECT APPROVED DPP-IV INHIBITOR DRUGS
The DPP-4 Inhibitor Domain
Select Approved DPP-4 Inhibitors Available in Developed Markets
Januvia - The Leading DPP-IV Inhibitor Drug Worldwide
Januvia Franchise (Merck & Co.)
Galvus (Novartis)
A Comparison of Januvia and Galvus
Pharmacological Comparison of Sitagliptin and Vildagliptin
Onglyza (AstraZeneca)
Tradjenta (Boehringer Ingelheim)
Nesina (Takeda Pharmaceutical)
TENELIA (Mitsubishi Tanabe & Daiichi Sankyo Co., Ltd.)
ZAFATEK (Takeda Pharmaceutical)
MARIZEV (Merck)

6. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS
Physiology of Glucose Homeostasis
Glucose Homeostasis in the Fasting Stage
Glucose Homeostasis in the Fed Stage
What is DPP-4?
Introduction to DPP-4 Inhibitors
Mechanism of Action of DPP-4 Inhibitors
Schematic Representation of DPP-IV Inhibitor' Mechanism of Action
DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications
Advantages of DPP-4 Inhibitors
Type-2 Diabetes - The Most Prevalent Form of Diabetes
Bio-chemistry of T2DM

7. COMPETITIVE LANDSCAPE

7.1 Focus on Select Global Players

7.2 Recent Industry Activity
MSD Receives Marketing Approval for SUJANU Combination Tablets in Japan
Boehringer Ingelheim and Lilly Announces Cardiovascular Outcome Trial for Tradjenta's CARMELINA
Fixed-Dose Combination STEGLUJAN Receives Approval from US FDA
AstraZeneca Receives FDA Approval for Qtern
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd. Announces the Launch of CANALIA Combination Tablets
Merck Drops Omarigliptin Filing in the US and EU
FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines
First Real-world Evidence Hints at Greater Efficacy of SGLT2 Inhibitors
BoehringerIngelheim Pharmaceuticals, Inc. and Eli Lilly and Company Receives FDA Approval for Glyxambi Tablets

8. GLOBAL MARKET PERSPECTIVE

9. REGIONAL MARKET PERSPECTIVE

9.1 The United States
A. Market Analysis
List of FDA-Approved DPP-4 Inhibitors in the US
Januvia Leads the Way, FDA's Heart Failure Warning Impacts Performance
FDA's Latest Issue of Heart Failure Warning on DPP-4 Inhibitors - Potential Market Threat
Increasing Diabetes Incidence in the US
B. Market Analytics

9.2 Canada
A. Market Analysis
Diabetes Statistics
B. Market Analytics

9.3 Japan
A. Market Analysis
Japan - An Important Market for DPP-IV Inhibitors
List of DPP-4 Inhibitors in the Japanese Market
B. Market Analytics

9.4 Europe
A. Market Analysis
Current & Future Analysis
DPP-IV Inhibitors Available in the European Market
Diabetes Statistics in Europe
B. Market Analytics

9.4.1 France
Market Analysis

9.4.2 Germany
Market Analysis

9.4.3 Italy
Market Analysis

9.4.4 The United Kingdom
A. Market Analysis
Rising Obesity Cases - Increased Risk of Diabetes
NHS England Launches Action for Diabetes Plan
B. Market Analytics

9.4.5 Russia
A. Market Analysis
Rising Diabetes Prevalence Presents Opportunity for DPP-IV inhibitors Market
B. Market Analytics

9.4.6 Rest of Europe
Market Analysis

9.5 Asia-Pacific
A. Market Analysis
Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors
Aging Populace - Potential Opportunities
Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities
China & India Offer High Potential
Asia Suffers from Lack of Focus on Diabetes Care
Healthcare Societies and Associations Spread Awareness of Diabetes
B. Market Analytics

9.5.1 China
A. Market Analysis
Current & Future Analysis
China: A Market with Huge Untapped Potential for DPP-4 Inhibitor Drugs
Robust Growth Ahead Despite Initial Lag
B. Market Analytics

9.5.2 India
A. Market Analysis
DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
Diabetic Epidemic in the Country to Spur Market Growth
B. Market Analytics

9.5.3 South Korea
A. Market Analysis
Rising Competition in the Korean DPP-4 Inhibitor Market
B. Market Analytics

9.5.4 Rest of Asia-Pacific
A. Market Analysis
Current & Future Analysis
Australia
Rising Incidence of Diabetes
Australia: Rising Diabetes Prevalence Presents Opportunity for DPP-IV inhibitors Market
B. Market Analytics

9.6 Rest of World
A. Market Analysis
Current & Future Analysis
Latin America: National Diabetes Programs
Diabetes in Latin America - A Glance at Key Statistics
Key Opportunity Indicator: Aging Population
A Peek at Brazilian Diabetes Market
United Arab Emirates: Rising Diabetic Cases to Propel Market Demand
Key Statistics: Diabetes Prevalence in Middle East and African Regions
B. Market Analytics

10. COMPANY PROFILES

Total Companies Profiled: 14 The United States (2)

• Japan (6)
• Europe (3)
• Germany (1)
• The United Kingdom (1)
• Rest of Europe (1)
• Asia-Pacific (Excluding Japan) (3)
  

For more information about this report visit https://www.researchandmarkets.com/research/sz3qtz/global_dppiv?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com